Elser Financial Planning 13F: New $218K Stake in ABT

Elser Financial Planning disclosed on October 16, 2026, that it has taken a new position in Abbott Laboratories (NYSE: ABT), acquiring 2,209 shares valued at approximately $218,315. This marks the fund's first investment in the company.

What Changed in Elser Financial Planning's Abbott Position

Elser Financial Planning opened a new position in Abbott Laboratories with 2,209 shares, marking a fresh investment in the healthcare sector.

Other Institutional Activity in Abbott

Several other institutional investors have also made moves in Abbott Laboratories. Blackrock Inc. holds 152,563,476 shares valued at about $16 billion, having increased its stake by 6,876,428 shares, a 4.7% rise. Vanguard Capital Management LLC has 113,750,994 shares worth roughly $11.9 billion, adding 801,938 shares, up 0.7%. Meanwhile, State Street Corporation owns 80,926,234 shares valued at around $8.5 billion, increasing its holdings by 1,352,749 shares, a 1.7% uptick.

Abbott Laboratories Stock Up 2.3%

As of October 16, 2026, Abbott Laboratories' shares traded recently around $104.70, which is below their 50-day moving average of $105.93 by 1.2%. The stock is also significantly below its 52-week high of $132.03, down about 20.7%. However, it's above its 52-week low of $81.97 by 27.7%, indicating some resilience in the current market environment.

Recent Earnings

For the trailing twelve months, Abbott reported revenue of approximately $46.6 billion, reflecting a year-over-year growth of 13.0%. Its earnings per share (EPS) stood at $3.10, supported by a net margin of 11.6% and a return on equity (ROE) of 10.6%. The next earnings report is expected to be released on October 21, 2026.

Insider Buying and Selling at Abbott Laboratories

On May 7, 2026, Director John G. Stratton bought 2,000 shares at an average price of $86.82, totaling $173,640. In contrast, Officer Louis H. Morrone sold 5,850 shares on August 11, 2026, at an average price of $109.83, which was valued at $642,506. CEO Robert B. Ford also sold 398,832 shares on August 25, 2026, totaling approximately $46.2 million.

Analysts Set New Price Targets

On October 16, 2026, TD Cowen maintained its 'Buy' rating on Abbott Laboratories with a price target of $135. This follows earlier ratings, including an upgrade from Rothschild & Co on October 2, setting a target at $127. The consensus price target across analysts is $120.71, based on 26 opinions, indicating strong confidence in Abbott's growth potential.

About Abbott Laboratories

Abbott Laboratories, based in Abbott Park, Illinois, develops and sells healthcare products worldwide. Its operations span four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. This recent investment from Elser Financial Planning highlights growing interest in the healthcare sector, especially as Abbott continues to expand its offerings.

Bottom Line

Abbott Laboratories is seeing notable activity from institutional investors, including a fresh stake from Elser Financial Planning. With earnings scheduled for October 21, investors will be keen to see how the company performs moving forward. The recent 13F filing reflects holdings as of the reporting period and may not represent the investor's current position. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.